The use of a GLP‐1 RA with proven CV benefit is recommended for persons with T2D and CKD who do not meet their individualized glycemic target with metformin alone, in combination with an SGLT2 inhibitor or an SGLT2 inhibitor alone. This evidence concerns the gene SLC5A2 and chronic kidney disease.